Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OpSCF

Monoclonal antibody · developed by Insmed

Phase 2 Most advanced trial (none active)
INSM Developer
1 Registered trials

What is OpSCF?

OpSCF is a humanized IgG4 kappa antibody also known as SCF248. It is studied in atopic dermatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Humanized IgG4k, SCF248
Drug type
Monoclonal antibody
Therapy area
Dermatology
Developer
Insmed Incorporated (INSM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06101823 Phase 2 Atopic Dermatitis Completed INSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic Dermatitis

More from Insmed

Follow INSM, the company behind OpSCF

See INSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INSM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.